KEGG   DRUG: OmalizumabHelp
Entry
D05251                      Drug                                   

Name
Omalizumab (USAN/INN);
Omalizumab (genetical recombination) (JAN);
Xolair (TN)
Product
Remark
Therapeutic category: 2290 4490
ATC code: R03DX05
Product: D05251<JP/US>
Efficacy
Antiasthmatic, Urticaria therapeutic agent, Mediator release inhibitor, Anti-IgE antibody
  Disease
Asthma [DS:H00079]
Comment
Monoclonal antibody
Target
FCER1A [HSA:2205] [KO:K08089]
  Pathway
hsa04664  Fc epsilon RI signaling pathway
hsa05310  Asthma
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 R RESPIRATORY SYSTEM
  R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
   R03D OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
    R03DX Other systemic drugs for obstructive airway diseases
     R03DX05 Omalizumab
      D05251  Omalizumab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Immunological Agents
  Immunological Agents, Other
   Miscellaneous
    Omalizumab
     D05251  Omalizumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 2  Agents affecting individual organs
  22  Respiratory organ agents
   229  Miscellaneous
    2290  Miscellaneous
     D05251  Omalizumab (USAN/INN); Omalizumab (genetical recombination) (JAN)
 4  Agents affecting cellular function
  44  Allergic agents
   449  Miscellaneous
    4490  Miscellaneous
     D05251  Omalizumab (USAN/INN); Omalizumab (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
 Not elsewhere classified
  Organismal systems
   Immune system
    FCER1A
     D05251  Omalizumab (USAN/INN) <JP/US>
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D05251
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D05251
BRITE hierarchy
Other DBs
CAS: 242138-07-4
PubChem: 47206967
DrugBank: DB00043
NIKKAJI: J2.104.950F

» Japanese version   » Back

DBGET integrated database retrieval system